Insider Transactions in Q2 2023 at Ambrx Biopharma Inc. (AMAM)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 07
2023
|
Steve C Glover Director |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+50.0%
|
-
|
|
Jun 07
2023
|
Kate Hermans Director |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+50.0%
|
-
|
|
Jun 07
2023
|
Paul V Maier Director |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+50.0%
|
-
|
|
Jun 07
2023
|
Janet Loesberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+50.0%
|
-
|
|
Apr 26
2023
|
Daniel J. O'Connor President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
2,750,000
+50.0%
|
-
|
|
Apr 26
2023
|
Sonja Nelson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,000,000
+50.0%
|
-
|
|
Apr 20
2023
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
886,634
+1.3%
|
$9,752,974
$11.6 P/Share
|
|
Apr 19
2023
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
951,909
+1.41%
|
$10,470,999
$11.15 P/Share
|
|
Apr 18
2023
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
3,376,646
+4.9%
|
$37,143,106
$11.27 P/Share
|
|
Apr 17
2023
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
562,121
+0.9%
|
$5,621,210
$10.67 P/Share
|
|
Apr 14
2023
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
841,967
+1.35%
|
$7,577,703
$9.96 P/Share
|
|
Apr 13
2023
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
1,193,808
+1.93%
|
$10,744,272
$9.16 P/Share
|